What is a stock summary page? Click here for an overview.
Business Description
Argenica Therapeutics Ltd
ISIN : AU0000150328
Share Class Description:
ASX:AGN: Ordinary SharesDescription
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.86 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -22.3 | |||||
3-Year EPS without NRI Growth Rate | -22.3 | |||||
3-Year FCF Growth Rate | -17.8 | |||||
3-Year Book Growth Rate | 6.3 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 29.81 | |||||
9-Day RSI | 39.92 | |||||
14-Day RSI | 44.81 | |||||
3-1 Month Momentum % | 24.8 | |||||
6-1 Month Momentum % | 13.04 | |||||
12-1 Month Momentum % | 18.18 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.95 | |||||
Quick Ratio | 6.95 | |||||
Cash Ratio | 6.8 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19.1 | |||||
Shareholder Yield % | -11.61 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -46.75 | |||||
ROA % | -39.03 | |||||
ROIC % | -1104.8 | |||||
3-Year ROIIC % | -929.45 | |||||
ROCE % | -46.74 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 7.33 | |||||
Price-to-Tangible-Book | 7.55 | |||||
EV-to-EBIT | -15.89 | |||||
EV-to-EBITDA | -15.89 | |||||
EV-to-FCF | -16.89 | |||||
Price-to-Net-Current-Asset-Value | 7.55 | |||||
Price-to-Net-Cash | 7.55 | |||||
Earnings Yield (Greenblatt) % | -6.3 | |||||
FCF Yield % | -5.17 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Argenica Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil A$) | |||
EPS (TTM) (A$) | -0.048 | ||
Beta | 1.32 | ||
3-Year Sharpe Ratio | 0.31 | ||
3-Year Sortino Ratio | 0.52 | ||
Volatility % | 44.73 | ||
14-Day RSI | 44.81 | ||
14-Day ATR (A$) | 0.036791 | ||
20-Day SMA (A$) | 0.7785 | ||
12-1 Month Momentum % | 18.18 | ||
52-Week Range (A$) | 0.535 - 0.985 | ||
Shares Outstanding (Mil) | 128.09 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Argenica Therapeutics Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Argenica Therapeutics Ltd Stock Events
Event | Date | Price (A$) | ||
---|---|---|---|---|
No Event Data |
Argenica Therapeutics Ltd Frequently Asked Questions
What is Argenica Therapeutics Ltd(ASX:AGN)'s stock price today?
The current price of ASX:AGN is A$0.76. The 52 week high of ASX:AGN is A$0.99 and 52 week low is A$0.54.
When is next earnings date of Argenica Therapeutics Ltd(ASX:AGN)?
The next earnings date of Argenica Therapeutics Ltd(ASX:AGN) is .
Does Argenica Therapeutics Ltd(ASX:AGN) pay dividends? If so, how much?
Argenica Therapeutics Ltd(ASX:AGN) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |